Sumit Chanda, Ph.D.

Sumit Chanda's Research Focus

Infectious Diseases, HIV/AIDS, Pandemic Influenza, Inflammatory/Autoimmune Disease, Arthritis, Crohn’s Disease (Colitis), Psoriasis, Scleroderma, Systemic Lupus Erythematosus, Cancer
Viruses are obligate pathogens, and therefore their survival is dependent upon their ability to exploit host cellular machinery. Concurrently, viruses must also successfully evade immune surveillance mechanisms, including first-line (innate) defense systems. The Chanda lab is interested in unraveling the molecular bases for these complex host-pathogen interactions, which will not only provide insight into viral pathogenesis, but key regulators of inflammation and innate immunity in cancer.

Sumit Chanda's Research Report

We are studying cellular proteins required for both influenza A and retrovirus/HIV infection. Also, we are investigating novel molecules that regulate or respond to Pattern Recognition Receptor (PRR) signaling. Taken together, we aim to elucidate the repertoire of host proteins required for viral infection, and understand the molecular strategies adapted by these viruses as countermeasures to innate immune responses. 

To understand these events on a global level, our lab uses a series of systems-level approaches, including genome-wide RNAi, proteomics and protein-protein interaction (PPI) analysis, and high content imaging. These, and other, tools are helping us to build a comprehensive cellular "roadmap" exploited by these viruses to enable their propagation within a cell. These studies are expected to provide unprecedented insight into the molecular circuitry commandeered by these pathogens to establish infection, and will offer new opportunities for the development of "next generation" host factor and immune-mediated antivirals.

Sumit Chanda's Bio

Sumit Chanda earned his Ph.D. from Stanford University in 2001, and received his post-doctoral training at the Genomics Institute of the Novartis Research Foundation (GNF). He subsequently transitioned to a Group Leader position, and established his research group in the Division of Cellular Genomics at GNF. In 2007, he joined the Infectious and Inflammatory Disease Center at Sanford Burnham Prebys as an Associate Professor. Dr. Chanda also holds an Adjunct Professor appointment at the Salk Institute for Biological Studies, as well as a Visiting Scientist position at the Genomics Institute of the Novartis Research Foundation.


Other Appointments

Adjunct Professor, Salk Institute for Biological Sciences
Visiting Scientist, The Genomics Institute of the Novartis Research Foundation
Visiting Scientist, The Scripps Research Institute

IPP Accessory


NLRX1 Sequesters STING to Negatively Regulate the Interferon Response, Thereby Facilitating the Replication of HIV-1 and DNA Viruses.

Guo H, König R, Deng M, Riess M, Mo J, Zhang L, Petrucelli A, Yoh SM, Barefoot B, Samo M, Sempowski GD, Zhang A, Colberg-Poley AM, Feng H, Lemon SM, Liu Y, Zhang Y, Wen H, Zhang Z, Damania B, Tsao LC, Wang Q, Su L, Duncan JA, Chanda SK, Ting JP

Cell Host Microbe 2016 Apr 13 ;19(4):515-528

A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals.

Riva L, Yuan S, Yin X, Martin-Sancho L, Matsunaga N, Burgstaller-Muehlbacher S, Pache L, De Jesus PP, Hull MV, Chang M, Chan JF, Cao J, Poon VK, Herbert K, Nguyen TT, Pu Y, Nguyen C, Rubanov A, Martinez-Sobrido L, Liu WC, Miorin L, White KM, Johnson JR, Benner C, Sun R, Schultz PG, Su A, Garcia-Sastre A, Chatterjee AK, Yuen KY, Chanda SK

bioRxiv 2020 Apr 17 ;

Sensor Sensibility-HIV-1 and the Innate Immune Response.

Yin X, Langer S, Zhang Z, Herbert KM, Yoh S, König R, Chanda SK

Cells 2020 Jan 20 ;9(1)

Show All Select Publications

Sec61 Inhibitor Apratoxin S4 Potently Inhibits SARS-CoV-2 and Exhibits Broad-Spectrum Antiviral Activity.

Pohl MO, Martin-Sancho L, Ratnayake R, White KM, Riva L, Chen QY, Lieber G, Busnadiego I, Yin X, Lin S, Pu Y, Pache L, Rosales R, Déjosez M, Qin Y, De Jesus PD, Beall A, Yoh S, Hale BG, Zwaka TP, Matsunaga N, García-Sastre A, Stertz S, Chanda SK, Luesch H

ACS Infect Dis 2022 Jul 8 ;8(7):1265-1279

Synthetic lethality-based prediction of anti-SARS-CoV-2 targets.

Pal LR, Cheng K, Nair NU, Martin-Sancho L, Sinha S, Pu Y, Riva L, Yin X, Schischlik F, Lee JS, Chanda SK, Ruppin E

iScience 2022 May 20 ;25(5):104311

NFAM1 Promotes Pro-Inflammatory Cytokine Production in Mouse and Human Monocytes.

Juchem KW, Gounder AP, Gao JP, Seccareccia E, Yeddula N, Huffmaster NJ, Côté-Martin A, Fogal SE, Souza D, Wang SS, Glynn ERA, Yung I, Ritchie J, Li L, Zheng J, Mbow ML, Li J, Chanda SK

Front Immunol 2021 ;12:773445

Development of an In Vivo Probe to Track SARS-CoV-2 Infection in Rhesus Macaques.

Madden PJ, Arif MS, Becker ME, McRaven MD, Carias AM, Lorenzo-Redondo R, Xiao S, Midkiff CC, Blair RV, Potter EL, Martin-Sancho L, Dodson A, Martinelli E, Todd JM, Villinger FJ, Chanda SK, Aye PP, Roy CJ, Roederer M, Lewis MG, Veazey RS, Hope TJ

Front Immunol 2021 ;12:810047

A combined EM and proteomic analysis places HIV-1 Vpu at the crossroads of retromer and ESCRT complexes: PTPN23 is a Vpu-cofactor.

Stoneham CA, Langer S, De Jesus PD, Wozniak JM, Lapek J, Deerinck T, Thor A, Pache L, Chanda SK, Gonzalez DJ, Ellisman M, Guatelli J

PLoS Pathog 2021 Nov ;17(11):e1009409

Genome-scale metabolic modeling reveals SARS-CoV-2-induced metabolic changes and antiviral targets.

Cheng K, Martin-Sancho L, Pal LR, Pu Y, Riva L, Yin X, Sinha S, Nair NU, Chanda SK, Ruppin E

Mol Syst Biol 2021 Nov ;17(11):e10260

Show All Publications